Cargando…

2384. The Relationship Between Rifaxamin Use and the Prevalence of Clostridiodes difficile and Vancomycin-Resistant Enterococcus in Patients with Advanced Liver Disease

BACKGROUND: Rifaximin (RFX) is a minimally absorbed antibiotic that achieves high concentrations after administration in the gut lumen. Previously, RFX showed activity against Clostridiodes difficile (C. difficile) recurrences post treatment with little overall impact on the normal fecal microbiota....

Descripción completa

Detalles Bibliográficos
Autores principales:	Alberto. De Jesus, Francisco, Kuper, Kristi, Haider, Alyzeh, Sackey, Joachim, Finkel, Diana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810353/ http://dx.doi.org/10.1093/ofid/ofz360.2062

Ejemplares similares

Concomitant Vancomycin-Resistant Enterococcus faecium and Clostridium difficile Colitis
por: Mehershahi, Shehriyar, et al.
Publicado: (2021)

Updates and Opinions in Diagnosis and Treatment of Clostridiodes difficile in Pediatrics
por: Malhotra, Sanchi, et al.
Publicado: (2021)

Risk for Clostridiodes difficile Infection among Older Adults with Cancer
por: Kamboj, Mini, et al.
Publicado: (2019)

972. Asymptomatic Carriage of Clostridiodes difficile and Risk of Subsequent Infection
por: Espiritu, Katrina, et al.
Publicado: (2018)

779. Clostridiodes difficile: Is it time for surveillance! Cost-benefit analysis
por: Yassin, Mohamed, et al.
Publicado: (2020)

A Predictive Model to Identify Complicated Clostridiodes difficile Infection
por: Berinstein, Jeffrey A, et al.
Publicado: (2023)

Letter to editor ‘prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with Rifaxamin’
por: Elzubeir, Amera, et al.
Publicado: (2020)

Descriptive Study of Gut Microbiota in Infected and Colonized Subjects by Clostridiodes difficile
por: Sánchez-Pellicer, Pedro, et al.
Publicado: (2021)

397. Oral Vancomycin Versus Fidaxomicin for Clostridiodes difficile: A Comparative Retrospective Evaluation across a Large, Multi-center Healthcare System
por: Roemer, Kaleb, et al.
Publicado: (2022)

2393. Dimensions of Cumulative Antibiotic Exposure and Risk of Hospital Onset Clostridiodes Difficile
por: Song, Jiyoun, et al.
Publicado: (2019)

Management and characteristics of patients suffering from Clostridiodes difficile infection in primary care
por: Klezovich-Bénard, Maria, et al.
Publicado: (2021)

753. Impact of COVID-19 on Healthcare Facility-Onset Clostridiodes difficile Infection
por: Suleyman, Geehan, et al.
Publicado: (2021)

749. A Nurse-Driven Protocol for Early Detection of Clostridiodes difficile Infections
por: Beckman, Shannon, et al.
Publicado: (2021)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

708. Three Stages of Laboratory Stewardship in Improving Appropriate Clostridiodes Difficile Testing
por: Beckman, Shannon, et al.
Publicado: (2023)

Two Groups of Cocirculating, Epidemic Clostridiodes difficile Strains Microdiversify through Different Mechanisms
por: Murillo, Tatiana, et al.
Publicado: (2018)

Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020
por: Lakkasani, Saraswathi, et al.
Publicado: (2020)

2346. Cost Savings Associated with Implementation of Clinical Decision Support for Clostridiodes difficile Testing
por: Hoegg, Cindy L, et al.
Publicado: (2019)

Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review
por: Gupta, Akshita, et al.
Publicado: (2021)

Rate and predictors of 30-day readmission for clostridiodes difficile: a United States analysis
por: Kichloo, Asim, et al.
Publicado: (2022)

670. Clinical Characteristics and Outcomes in Patients with Healthcare Facility-Onset Clostridiodes difficile Infections
por: Joshi, Seema, et al.
Publicado: (2023)

798. Metronidazole Exposure Prior to Clostridiodes difficile Infection (CDI) is a Risk Factor for Severe C. difficile Disease in Cancer Patients
por: Francisco, Denise Marie A, et al.
Publicado: (2020)

Rational design of a microbial consortium of mucosal sugar utilizers reduces Clostridiodes difficile colonization
por: Pereira, Fátima C., et al.
Publicado: (2020)

2379. It’s Getting Complicated: Outcomes of Clostridiodes difficile PCR Positive/Toxin-Negative Patients
por: Morillas, Jose A, et al.
Publicado: (2019)

2424. Shedding of Viable Clostridiodes difficile in Patients Admitted to a Medical Intensive Care Unit
por: Young, Vincent B, et al.
Publicado: (2019)

In veteran outpatients, antibiotics remain significant risk factor for community-acquired Clostridiodes difficile infection
por: Akpoji, Ukwen, et al.
Publicado: (2022)

Evidence of within-facility patient–patient Clostridiodes difficile infection spread across diverse settings
por: Justice, Samuel, et al.
Publicado: (2022)

The real efficacy of microbiota restoration following standard of care antimicrobial in patients with recurrent Clostridiodes difficile
por: Sehgal, Kanika, et al.
Publicado: (2023)

Vancomycin-resistant Enterococcus faecium COLONIZATION and Clostridium difficile infection in a HEMATOLOGIC patient
por: Goić-Barišić, Ivana, et al.
Publicado: (2020)

The Association Between the Frequency of Interruptions in Antibiotic Exposure and the Risk of Health Care-Associated Clostridiodes difficile Infection
por: Song, Jiyoun, et al.
Publicado: (2020)

2359. Prospective Feasibility Study for Novel Ultrasensitive Multiplexed Immunoassay for Clostridiodes difficile Toxins A and B
por: Watson, Lauren, et al.
Publicado: (2019)

706. Effect of the Covid-19 Pandemic on Rates of Recurrent Clostridiodes difficile Infection in the Veterans Affairs System
por: Drekonja, Dimitri M, et al.
Publicado: (2021)

Engineered Secretory Immunoglobulin A provides insights on antibody-based effector mechanisms targeting Clostridiodes difficile
por: Bharathkar, Sonya Kumar, et al.
Publicado: (2023)

2384. Multidrug-Resistant Gram-Negative Infections Treated With Ceftolozane–Tazobactam: Impact of Delayed Initiation
por: Jorgensen, Sarah, et al.
Publicado: (2018)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

Comparative Effectiveness of Vancomycin vs. Metronidazole in Mild Clostridium difficile Infections, and Potential Impact on Subsequent Vancomycin-Resistant Enterococcus (VRE) Isolation
por: Youngster, Ilan, et al.
Publicado: (2017)

747. Association of Clostridiodes difficile Infection Incidence With Renewed Vigor in Infection Prevention Practices With the Onset of the COVID-19 Pandemic
por: Khan, Ahmed A, et al.
Publicado: (2021)

Refractory Clostridium difficile Infection Cured With Fecal Microbiota Transplantation in Vancomycin-Resistant Enterococcus Colonized Patient
por: Jang, Mi-Ok, et al.
Publicado: (2015)

Clostridiodes difficile Treatment Guided by Polymerase Chain Reaction Stool Testing Does not Alter Outcomes for Patients With Inflammatory Bowel Disease
por: Chandrabos, Ceena, et al.
Publicado: (2021)

Reduction of Clostridium Difficile and vancomycin-resistant Enterococcus contamination of environmental surfaces after an intervention to improve cleaning methods
por: Eckstein, Brittany C, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ivt50jgej07mv1eup2anosuu5e